The earnings are overshadowed by pipeline catalysts—focus on the upcoming ZENITH-AD Phase 3 initiation and End-of-Phase 2 meeting with FDA for alopecia areata. The strong cash position reduces near-term dilution risk, but the EPS miss may pressure the stock. Monitor for clinical data readouts in H2 2026.
Price Chart
Executive Summary
Nektar Therapeutics reported Q1 2026 revenue of $10.9M (+3.8% YoY) and a net loss of $44.9M ($1.82 per share), improving from a $50.9M loss in Q1 2025. The EPS of -$1.82 missed the consensus estimate of -$1.74 by 4.6%. The balance sheet strengthened significantly with $731.6M in cash and investments following recent capital raises totaling ~$834M in February and April 2026.
Key Financial Metrics
Key Facts
- Revenue $10.9M vs $10.5M YoY (+3.8%)
- Net loss $44.9M vs $50.9M YoY (improved)
- EPS -$1.82 vs consensus -$1.74 (4.6% miss)
- Cash and investments $731.6M at Mar 31, 2026 (up from $245.8M at Dec 31, 2025)
- Recent offerings raised ~$834M: $460M in Feb and $374M in Apr 2026
- Phase 3 ZENITH-AD program in atopic dermatitis to initiate by July 2026
Financial Impact
Revenue growth minimal; net loss improved by 12% YoY; cash position strengthened by ~$486M from offerings
Risk Factors
- Clinical trial failure risk for rezpegaldesleukin
- Continued operating losses with no near-term product revenue
- Share dilution from recent offerings (though already executed)
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001213900-26-053369 |
| Document: ea0289611-8k_nektar.htm | 0001213900-26-053369 |
| Document: 0001213900-26-053369-index-headers.html | 0001213900-26-053369 |
| Document: 0001213900-26-053369-index.html | 0001213900-26-053369 |
| Document: 0001213900-26-053369.txt | 0001213900-26-053369 |
| 8-K Data (Synthetic) | 0001213900-26-053369 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Aug 13, 2026 9w ago | Press Release | $73.02 $68.50 | ▼ −6.19% | ▼ −4.20% | $35.78 (−51.00%) |
Aug 9, 2026 10w ago | Institutional Cluster | $74.86 $75.44 | ▲ +0.77% | ▲ +1.69% | $35.78 (−52.20%) |
Aug 7, 2026 10w ago | Court Ruling | $76.48 $74.19 | ▼ −2.99% | ▼ −2.60% | $35.78 (−53.22%) |
Jul 28, 2026 11w ago | Press Release | $70.68 $73.77 | ▲ +4.37% | ▼ −0.65% | $35.78 (−49.38%) |
Jun 11, 2026 18w ago | Institutional Cluster | $59.21 $72.92 | ▲ +23.15% | ▲ +21.26% | $35.78 (−39.57%) |
Jun 11, 2026 18w ago | Institutional Cluster | $59.21 $72.92 | ▲ +23.15% | ▲ +21.26% | $35.78 (−39.57%) |
May 21, 2026 21w ago | Insider Cluster | $66.61 $65.25 | ▲ +2.04% | ▲ +0.63% | $35.78 (+46.28%) |
May 8, 2026 23w ago | 8-K | $78.72 $56.23 | ▲ +28.57% | ▲ +28.27% | $35.78 (+54.55%) |
May 7, 2026 23w ago | 8-K | $81.89 $57.32 | ▼ −30.00% | ▼ −30.03% | $35.78 (−56.31%) |
Apr 24, 2026 25w ago | DEFA14A | $86.74 $65.56 | ▼ −24.42% | ▼ −29.37% | $35.78 (−58.75%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access